SK Chemical is approved on the ‘Cell Culture-type Flu Vaccine’ for the first time in Korea and the third time internationally
SK Chemical (executive director and CEO Man-hoon Park) announced that the company acquired a product license for the first cell culture-type flu vaccine ‘skyCellflu’ in Korea from the Ministry of Food and Drug Safety on the 26th. This is the third commercialized success after Norvatis and Baxter....
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
